Skip to content

Renal Nerves Stimulation Study

Feasibility of Electrical Mapping and Stimulation of Renal Arteries in Patients Undergoing Renal Denervation

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02496117
Acronym
RNS
Enrollment
56
Registered
2015-07-14
Start date
2014-03-14
Completion date
2019-07-04
Last updated
2020-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Renal Denervation

Brief summary

Study design: Investigator initiated, single centre, feasibility study Main objectives are twofold: 1. To investigate the feasibility of RNS in patients with therapy resistant hypertension, which is assessing the functional distribution of renal nerves using 3D imaging and differential pacing modalities. 2. To investigate the blood pressure responses and cardiac excitable properties to RNS, and subsequently perform a RDN procedure, guided by 3D mapping by two different techniques e.g. RNS-checked RDN and RNS-guided RDN procedures. Study population: 40 patients (18 - 80 yr old)

Detailed description

Background: Approximately 10-15% of adults with hypertension are considered to be treatment resistant because their hypertension is uncontrolled despite taking three or more drugs that includes a diuretic. Renal denervation (RDN) is a novel treatment option for therapy resistant hypertension and its rationale originates in denervating the renal sympathetic efferent and afferent coupling with the central autonomic nervous system. By denervating the renal arteries, general sympathetic tone is reduced. Currently, RDN is performed by placing in a spiral pattern 5-6 ablation lesions in each renal artery. 15-30% of the patients do not have any benefit from this procedure. The reason for this is unknown. Experimental data show that renal nerve stimulation (RNS) may serve as a functional endpoint to assess completeness of the RDN procedure. A RNS-guided RDN may prove to be superior to standard RDN (RNS-checked) in blood pressure control. Main objectives are twofold: 1. To investigate the feasibility of RNS in patients with therapy resistant hypertension, which is assessing the functional distribution of renal nerves using 3D imaging and differential pacing modalities. 2. To investigate the blood pressure responses and cardiac excitable properties to RNS, and subsequently perform a RDN procedure, guided by 3D mapping by two different techniques e.g. RNS-checked RDN and RNS-guided RDN procedures. Secondary objective: The secondary objective is to compare both techniques (RNS-checked vs. RNS-guided) in terms of efficacy and safety. Hypotheses: * We hypothesize that identification and localization of the sympathetic nerve bundles using 3D navigation systems and selective pacing manoeuvres will allow a functional approach to denervate the kidneys and improve the success rate of this procedure in patients with hypertension. * We hypothesize that the RNS-guided RDN procedure will show better blood pressure data during follow up, since the completeness has been assessed in contrast to the RNS-checked RDN procedure. Study design: Investigator initiated, single centre, prospective, feasibility study Study population: 40 patients (18 - 80 yr old) * 20 patients treated with RNS-checked RDN * 20 patients treated with RNS-guided RDN Intervention: Two different techniques will be used in this trial: 1. RNS-checked RDN 2. RNS-guided RDN Main study endpoints: Main study parameter will be the arterial blood pressure response to RNS prior to RDN and absence of blood pressure rise in response to pacing in the renal artery after RDN. Secondary study endpoints: Blood pressure at 3, 6, 12 months after the intervention, and change in blood pressure compared to measurement before the intervention.

Interventions

PROCEDUREElectrical mapping, nerve stimulation checked renal denervation procedure
PROCEDUREElectrial mapping, nerve stimulation guided renal denervation procedure

Sponsors

Diagram B.V.
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

RNS guided RDN

Intervention model description

RNS checked RDN

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* The patient is willing and able to comply with the protocol and has provided written informed consent. * Age 18-80 years * The patient has hypertension and is accepted for renal denervation or combined pulmonary bein isolation and renal denervation * Glomerular filtration rate \>45 mL/min * No history of renal artery stenosis

Exclusion criteria

* Type 1 diabetes mellitus * Contraindication to chronic anticoagulation therapy or heparin. * Chronic oxygen use * Primary pulmonary hypertension * Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertile age. * Known secondary cause of hypertension * Mental or physical inability to participate in the study. * Renal artery stenosis \>50% of the arterial lumen, or renal artery lumen ≤3 mm. * Dual or triple ipsilateral renal artery ostia.

Design outcomes

Primary

MeasureTime frameDescription
arterial blood pressure responseduring procedureMain study parameter will be the arterial blood pressure response to RNS prior to renal denervation and absence of blood pressure rise in response to pacing in the renal artery after RDN.

Secondary

MeasureTime frameDescription
blood pressure at 3 months3 months after the interventionBlood pressure at 3 months after the intervention
blood pressure at 6 months6 months after the interventionBlood pressure at 6 months after the intervention
blood pressure at 12 months12 months after the interventionBlood pressure at 12 months after the intervention
change in blood pressure compared to measurement before the interventionintervention - up to 12 months after the interventionchange in blood pressure compared to measurement before the intervention

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026